Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Finished Drug Prices
NA
1. Fg-4592
2. Fg4592
1. Fg-4592
2. 808118-40-3
3. Fg4592
4. Roxadustat (fg-4592)
5. Asp1517
6. N-[(4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]glycine
7. Asp 1517
8. 2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic Acid
9. Glycine, N-[(4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]-
10. Asp-1517
11. X3o30d9ymx
12. Fg-4592 (asp1517)
13. Chembl2338329
14. Fg 4592
15. (4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)glycine
16. (((4-hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl)amino)acetic Acid
17. Evrenzo
18. 2-(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxamido)acetic Acid
19. N-((4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl)glycine
20. N-[(4-hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl]glycine
21. 2-[(1-methyl-4-oxidanyl-7-phenoxy-isoquinolin-3-yl)carbonylamino]ethanoic Acid
22. Roxadustat [usan:inn]
23. Unii-x3o30d9ymx
24. Roxadustatum
25. N-((4-hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl)glycine
26. Glycine, N-((4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl)-
27. 8ho
28. Evrenzo (tn)
29. Fg-4592[roxadustat]
30. Roxadustat [inn]
31. Roxadustat [jan]
32. Roxadustat [usan]
33. Roxadustat(fg-4592)
34. Roxadustat [who-dd]
35. Mls006010023
36. Roxadustat (jan/usan/inn)
37. Schembl523705
38. Gtpl8454
39. Dtxsid60230644
40. Ex-a390
41. Chebi:132774
42. Bcpp000230
43. Hms3654m03
44. Amy16514
45. Bcp02523
46. Bdbm50431015
47. Fg-4592,asp1517
48. Mfcd20040519
49. S1007
50. Zinc71257465
51. Akos026674331
52. Bcp9000684
53. Ccg-268052
54. Cs-1094
55. Db04847
56. Sb16615
57. Ncgc00346527-01
58. Ncgc00346527-07
59. Ac-31003
60. As-17052
61. Hy-13426
62. Smr004701207
63. Db-075703
64. Sw219900-1
65. D10593
66. J-522733
67. Q27088611
68. 2-[[4-hydroxy-1-methyl-7-(phenoxy)isoquinoline-3-carbonyl]amino]acetic Acid
Molecular Weight | 352.3 g/mol |
---|---|
Molecular Formula | C19H16N2O5 |
XLogP3 | 3.4 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 5 |
Exact Mass | 352.10592162 g/mol |
Monoisotopic Mass | 352.10592162 g/mol |
Topological Polar Surface Area | 109 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 508 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
In clinical development for the treatment of anemia of chronic inflammatory disease.
Evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD).
FG-4592 represents one of several next generation PHI that has been optimized for multiple pharmacokinetic and pharmacodynamic parameters related to erythropoiesis, including selective inhibition of HIF prolyl and asparaginyl hydroxylases, potency, iron utilization, and ADME. FG-4592 represents one of several next generation HIF-PH inhibitors designed to selectively induce the expression of genes that mediate erythropoiesis for the treatment of anemia.
B03XA05
B - Blood and blood forming organs
B03 - Antianemic preparations
B03X - Other antianemic preparations
B03XA - Other antianemic preparations
B03XA05 - Roxadustat
Absorption
Orally active
FG-4592 is an orally active second generation HIF-PH inhibitor. Preclinical studies show that FG-4592 increases production of endogenous erythropoietin (EPO), increases iron mobilization and utilization, and overcomes the suppressive effects of inflammation on red blood cell production.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
ABOUT THIS PAGE
A Roxadustat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Roxadustat, including repackagers and relabelers. The FDA regulates Roxadustat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Roxadustat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Roxadustat manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Roxadustat supplier is an individual or a company that provides Roxadustat active pharmaceutical ingredient (API) or Roxadustat finished formulations upon request. The Roxadustat suppliers may include Roxadustat API manufacturers, exporters, distributors and traders.
click here to find a list of Roxadustat suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Roxadustat DMF (Drug Master File) is a document detailing the whole manufacturing process of Roxadustat active pharmaceutical ingredient (API) in detail. Different forms of Roxadustat DMFs exist exist since differing nations have different regulations, such as Roxadustat USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Roxadustat DMF submitted to regulatory agencies in the US is known as a USDMF. Roxadustat USDMF includes data on Roxadustat's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Roxadustat USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Roxadustat suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Roxadustat Drug Master File in Korea (Roxadustat KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Roxadustat. The MFDS reviews the Roxadustat KDMF as part of the drug registration process and uses the information provided in the Roxadustat KDMF to evaluate the safety and efficacy of the drug.
After submitting a Roxadustat KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Roxadustat API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Roxadustat suppliers with KDMF on PharmaCompass.
A Roxadustat written confirmation (Roxadustat WC) is an official document issued by a regulatory agency to a Roxadustat manufacturer, verifying that the manufacturing facility of a Roxadustat active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Roxadustat APIs or Roxadustat finished pharmaceutical products to another nation, regulatory agencies frequently require a Roxadustat WC (written confirmation) as part of the regulatory process.
click here to find a list of Roxadustat suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Roxadustat as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Roxadustat API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Roxadustat as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Roxadustat and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Roxadustat NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Roxadustat suppliers with NDC on PharmaCompass.
Roxadustat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Roxadustat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Roxadustat GMP manufacturer or Roxadustat GMP API supplier for your needs.
A Roxadustat CoA (Certificate of Analysis) is a formal document that attests to Roxadustat's compliance with Roxadustat specifications and serves as a tool for batch-level quality control.
Roxadustat CoA mostly includes findings from lab analyses of a specific batch. For each Roxadustat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Roxadustat may be tested according to a variety of international standards, such as European Pharmacopoeia (Roxadustat EP), Roxadustat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Roxadustat USP).
LOOKING FOR A SUPPLIER?